Among patients with resected stage 3 or 4 melanoma, treatment with immune-oncology agents such as Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated higher cure rates compared with those treated ...

The outcome of this study could significantly influence BioNTech’s stock performance and investor sentiment, especially if the combination therapy proves more effective than the standard treatment.

Adjuvant canakinumab did not increase disease-free survival in resected non–small-cell lung cancer.PURPOSEEffective treatments for resectable non–small-cell lung cancer (NSCLC) are limited and relapse ...

The incidence of early-onset pancreatic cancer (EOPC) is rising, yet optimal treatment strategies remain unclear. While adjuvant chemotherapy (ACT) has shown survival benefits in pancreatic ductal ...

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled ...

KEYNOTE-689 marks the first positive pivotal trial in two decades for resected, locally advanced HNSCC, and the findings have the potential to be practice-changing, Marjorie Green, head of ...

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ...

A 24-year-old female underwent excision of a 3-cm monophasic synovial sarcoma in the posterior low neck in Mexico. The tumor had 5 mitoses/10 hpf. The patient underwent another wide re-excision in ...

OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, to ...

The Company is awaiting feedback by mid-June 2025 from a Type D meeting with FDA regarding the statistical analysis plan to be used in an End of Phase 2 meeting for OST-HER2 in the prevention of ...